Vern C. Juel, M.D. – Lambert Eaton Myasthenic Syndrome (LEMS)

Submitted By:
Published Date:
January 25, 2020

Access Program Information

This is a continuing project to provide 3,4 diaminopyridine (DAP) under a treatment-use IND
to patients with Lambert-Eaton myasthenic syndrome (LEMS) and congenital myasthenic syndrome
(CMS).

Rare Disease:
Lymphangioleiomyomatosis